GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Cadence Pharmaceuticals, Inc. (CADX) [hlAlert]

Rating:
Buy CADX
up 196.18 %

Cadence Pharmaceuticals, Inc. (CADX) rated Buy with price target $7 by Collins Stewart

Posted on: Monday,  Nov 14, 2011  8:25 AM ET by Collins Stewart

Collins Stewart rated Buy Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) on 11/14/2011, when the stock price was $4.72. Since
then, Cadence Pharmaceuticals, Inc. has gained 196.19% as of 03/18/2014's recent price of $13.98.
If you would have followed this Collins Stewart's recommendation on CADX, you would have gained 196.18% of your investment in 855 days.

Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing its product candidates principally for use in the hospital setting. The Company has in-licensed rights to two late stage product candidates, Acetavance a intravenous formulation of acetaminophen and Omigard (omiganan pentahydrochloride) 1% aqueous gel. It has in-licensed the exclusive United States and Canadian rights to Acetavance, that is marketed in Europe for the treatment of acute pain and fever by Bristol-Myers Squibb Company (BMS). The Company has also in-licensed the rights to commercialize Omigard in North American and Europe.

Collins Stewart's research department is built around a number of sector-specialist teams. Our analysts are leaders in their area of specialisation and combine deep industry knowledge with decades of stock broking experience to produce insightful, independent sector research. Our research approach encompasses Questâ„¢ principles and focuses on cash-driven valuation techniques. Research is a Collins Stewart cornerstone; it is leveraged throughout the organisation.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/14/2011 8:25 AM Buy
None
4.72 7.00
as of 12/30/2011
1 Week up  8.21 %
1 Month down  -10.02 %
3 Months down  -16.31 %
1 YTD down  -16.31 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy